CEO and Chairman of the Executive Board
French Innate Pharma SA announced the appointment of Jonathan Dickinson as the Company’s newChief Executive Officer (CEO) and Chairman of the Executive Board. He succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process.
Jonathan Dickinson brings extensive biotech and pharma experience to Marseille-based Innate Pharma. He comes from Incyte, where he served as Executive Vice President and General Manager Europe since 2016. Prior to that, he gained significant leadership experience through several senior positions at oncology focused ARIAD Pharmaceuticals and Bristol-Myers Squibb. This followed a distinguished 13-year tenure at Hoffmann-La Roche, where he was instrumental in driving the success of several of the company’s flagship oncology therapies. Dickinson started his career at Novartis, holding roles of increasing responsibility within the oncology and endocrinology divisions. He holds a Bachelor of Science degree in Genetics and a Master of Business Administration from the University of Nottingham. For the next few months, Hervé Brailly will stay in an advisory role to ensure a smooth transition. It will be proposed that Dr Brailly joins the Board at the next opportunity.